Navigation Links
Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)

A Potential New Tool in the Diagnosis and Assessment of Asthma

EXTON, Pa., March 3 /PRNewswire/ -- Pharmaxis, Inc., a wholly owned subsidiary of Pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL), an emerging respiratory specialty pharmaceutical company, announced today that it has filed a New Drug Application (NDA), electronically, with the U.S. Food and Drug Administration (FDA) for Aridol(TM) (mannitol bronchial challenge test). Bronchial challenge tests are designed to assess bronchial hyperresponsiveness, an important marker in the diagnosis and assessment of asthma.

"A definitive asthma diagnosis and effective monitoring and management of the disease have been long-standing challenges for doctors and patients with asthma," said William Storms, MD, Allergist, Colorado Springs, CO. "The primary method of diagnosis -- a detailed history and physical examination of the patient, has remained relatively unchanged for many years and is largely absent of any routine test to confirm the diagnosis."

Brett Charlton MBBS, PhD, Medical Director, Pharmaxis Ltd, added, "Aridol is designed to measure bronchial hyperresponsiveness that corresponds with airway inflammation, an important underlying component of asthma."

Aridol will be a standardized test kit containing proprietary dry-powder mannitol (a naturally occurring sugar alcohol), prepared for delivery to the lungs using a proprietary hand-held inhaler. The goal of Aridol is to provide physicians and health care professionals with an objective measure of active airway inflammation through an easy-to-use, single-use test for asthma care and assessment in a variety of healthcare settings.

"Upon approval healthcare professionals will have an easy-to-administer bronchial challenge test improving their ability to diagnose and assess patients with asthma," said Stephen Beckman, President, Pharmaxis, Inc.

Aridol is approved for sale in Australia, major European countries and Korea. It is the first and only bronchial challenge test approved Europe-wide. Aridol has been included in various asthma, sport and occupational screening guidelines including; the GINA Report of Global Strategy for Asthma Management and Prevention, the U.S. Asthma Management Guidelines, the International Olympic Committee independent medical commission's guidelines for beta-2 agonist use in the 2008 Summer Olympics in Beijing, China, guidelines from the World Anti-Doping Agency, and those issued by other sports-governing bodies to ensure appropriate assessment and management of elite athletes who are asthmatic.

About Pharmaxis

Pharmaxis is an emerging respiratory specialty pharmaceutical company that researches, develops and commercializes new therapies for undertreated respiratory diseases. Its development pipeline includes: Aridol(TM) (mannitol bronchial challenge test) a tool to diagnose and assess asthma; Bronchitol(TM) (mannitol) for Cystic Fibrosis, bronchiectasis, and chronic obstructive pulmonary disease (COPD); PXS25 for the treatment of lung fibrosis; and PXS4159 for asthma. Founded in 1998, Pharmaxis Ltd is headquartered in Frenchs Forest, Australia with U.S. headquarters in Exton, PA. For more information, visit

SOURCE Pharmaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmaxis to Expand Manufacturing Capacity
2., Inc. Announces New Lead Developer
3. Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation
4. American Psychiatric Foundation Announces Recipients of Helping Hands Grants
5. Acuo Technologies(R) Announces Another Record Sales and Implementation Growth
6. CorNova Announces Addition of Andrew T. Jay, D.M.D., M.B.A., to its Board of Directors
7. Marketing Technology Solutions Announces Strong 2008 Growth and Web Site Enhancements for
8. Genoptix Announces Participation at Barclays Capital Global Healthcare Conference
9. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
10. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
11. WellPoint Announces Appearances at Upcoming Conferences
Post Your Comments:
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology: